Ginkgolide

Ginkgolides are a class of diterpene lactones extracted primarily from Ginkgo biloba leaves and roots, with ginkgolide B being the most pharmacologically studied compound. They act as potent antagonists of platelet-activating factor (PAF) receptors, which plays a role in platelet aggregation, inflammation, and neurological signaling.

Origin & History

Ginkgolides are a class of diterpene trilactones derived from the leaves of the ancient Ginkgo biloba tree. They are extracted through methods such as solvent extraction with ethanol or ethyl acetate, often followed by macroporous resin adsorption, chromatography, and crystallization.

Historical & Cultural Context

The research dossier lacks information on the traditional or historical medicinal uses of ginkgolides. The focus remains on extraction and chemical properties without addressing cultural contexts.

Health Benefits

• No specific health benefits are documented due to the lack of human clinical trials or RCTs.
• The research dossier does not provide data to support health claims.
• Extraction and isolation focus in studies preclude direct health implications.
• Typical research emphasizes chemical characterization over clinical application.
• There is no evidence-based health benefit due to an absence of clinical data.

How It Works

Ginkgolides, particularly ginkgolide B (BN 52021), function as selective competitive antagonists of the platelet-activating factor (PAF) receptor, blocking PAF-induced platelet aggregation and inflammatory cascade activation. Ginkgolide B also inhibits glycine receptor chloride channels in the central nervous system, modulating inhibitory neurotransmission. Additionally, some ginkgolides interfere with mitochondrial permeability transition pore (mPTP) opening, potentially reducing apoptotic signaling under oxidative stress conditions.

Scientific Research

The dossier does not reference any human clinical trials, RCTs, or meta-analyses for ginkgolides, reflecting a focus on extraction and chemical characterization methods.

Clinical Summary

Human clinical trials specifically isolating ginkgolides as standalone compounds are largely absent from the published literature, making it difficult to draw direct therapeutic conclusions. Most human research has been conducted on standardized Ginkgo biloba extracts (e.g., EGb 761), which contain 6% ginkgolides and bilobalide combined, complicating attribution of effects to ginkgolides alone. In vitro and animal studies have demonstrated ginkgolide B's PAF antagonism at micromolar concentrations, and small pilot studies in humans have noted reduced PAF-induced platelet aggregation ex vivo. Overall, the evidence base for isolated ginkgolide supplementation in humans remains preclinical, and robust RCTs with quantified outcomes are lacking.

Nutritional Profile

Ginkgolide is a bioactive terpenoid compound (specifically a diterpene trilactone) isolated from Ginkgo biloba, not a nutritional ingredient in the conventional sense and thus lacks macronutrient or micronutrient profile. It is not a source of protein, carbohydrates, fats, vitamins, or dietary fiber. Ginkgolides are classified into subtypes: Ginkgolide A, B, C, J, and M, with Ginkgolide B being the most pharmacologically studied. They are present in Ginkgo biloba leaf extracts at approximately 0.06–0.23% of dry leaf weight, and in standardized EGb 761 extract (the most studied commercial extract) ginkgolides constitute roughly 2.8–3.4% of the total extract by weight combined with bilobalide. Ginkgolide B is typically present at concentrations of 0.4–1.0 mg per standardized 120 mg EGb 761 dose. These compounds are lipophilic in nature, contributing to moderate oral bioavailability estimated at approximately 80% for Ginkgolide A and 60–70% for Ginkgolide B based on pharmacokinetic studies in human volunteers. They are not sources of calories or essential nutrients. Their biochemical significance lies solely in their role as platelet-activating factor (PAF) receptor antagonists, a pharmacological rather than nutritional property. No RDI or dietary reference intake exists for ginkgolides.

Preparation & Dosage

There are no clinically studied dosage ranges or forms reported in the research. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Ginkgo biloba leaf extract, bacopa monnieri, phosphatidylserine

Safety & Interactions

Ginkgolides, via their PAF-antagonist activity, may potentiate the effects of antiplatelet drugs such as aspirin, clopidogrel, and warfarin, increasing bleeding risk when combined. Reported adverse effects from Ginkgo biloba extracts containing ginkgolides include headache, gastrointestinal upset, and allergic skin reactions, though causation by ginkgolides specifically has not been isolated. Ginkgolide B's inhibition of glycine receptors raises theoretical concerns for individuals with seizure disorders, as glycinergic inhibition plays a role in seizure threshold. Pregnant and breastfeeding women are advised to avoid ginkgolide-containing supplements due to insufficient safety data and theoretical platelet-inhibiting risks.